FeesSafety
Pluang+

Hamborner REIT reports slight rental income drop and 6% FFO decline in Q3 2026 amid property sales and rising costs.

Company Fundamentals
10 Nov 2026, 14:31 WIB
Seeking Alpha
View Source
Neutral
Hamborner REIT reports slight rental income drop and 6% FFO decline in Q3 2026 amid property sales and rising costs.

Hamborner REIT's Q3 2026 results show a 0.9% decrease in rental income to EUR 67.3 million, primarily due to property disposals. Funds from operations (FFO) fell 6% to EUR 34.5 million, impacted by property sales, higher financing costs, and increased maintenance expenses. Key financial metrics remained stable, with a slight drop in loan-to-value ratio to 44.2% and a small decrease in EPRA NAV to EUR 8.85 per share. The company maintained a vacancy rate of 4.4% and a portfolio weighted average lease term of 5 years, indicating steady operational performance.

Hamborner REIT AG's Q3 2026 earnings provide context for real estate market activity. For readers following real estate stocks, here is Pluang's market snapshot as of Nov 10, 2026 19:13 WIB: Among 47 priced US real estate stocks, 20 rose and 17 fell. Notable movers include WELL (Welltower Inc.) at USD 246.50 with a -0.34% change, MAC (Macerich Company) at USD 25.21 with a -0.32% change, and IRM (Iron Mountain Inc) at USD 111.17 with a +0.29% change. The typical hold time on Pluang ranges from 9 to 81 days, with IRM showing the longest hold time of 81 days.

More News

Manufacturers expanding Microsoft 365 Copilot must review drawing revisions and supplier permissions to prevent data breaches.

Manufacturers expanding Microsoft 365 Copilot must review drawing revisions and supplier permissions to prevent data breaches.

The 2026 Verizon Data Breach Investigations Report links 61% of manufacturing breaches to third parties and 81% to internal data compromise. Manufacturers adopting Microsoft 365 Copilot should carefully manage which engineering and supplier files emp...

Market News
Neutral
57 minutes ago
Soleo Health chosen as specialty pharmacy partner for new FOP treatment Pasatru™

Soleo Health chosen as specialty pharmacy partner for new FOP treatment Pasatru™

Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...

Market News
Bullish
57 minutes ago
PsiThera secures $25M to advance oral immunology drugs targeting TNFα and TL1A pathways.

PsiThera secures $25M to advance oral immunology drugs targeting TNFα and TL1A pathways.

PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into l...

Company Fundamentals
Bullish
57 minutes ago
Opus Genetics reports Q3 2026 results, advances gene therapy trials, and extends cash runway to 2029

Opus Genetics reports Q3 2026 results, advances gene therapy trials, and extends cash runway to 2029

Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...

Company Fundamentals
Bullish
57 minutes ago
Iveco Group showcases new vehicles and tech at Fenatran 2026, boosting Latin America presence.

Iveco Group showcases new vehicles and tech at Fenatran 2026, boosting Latin America presence.

Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App